Published in Obesity and Diabetes Week, September 29th, 2003
"The lipophilic beta-adrenoreceptor antagonist propranolol and hydrophilic atenolol have been studied to define their pharmacokinetic and pharmacodynamic characteristics in obese patients," scientists in Poland report.
"A total of 43 subjects were allocated into three study groups: healthy, lean, normolipemic volunteers; obese normolipemic subjects; and obese patients with lipid disorders," said Jerzy Wojcicki and colleagues at the Pomeranian Academy of Medicine. "A...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week